Timmune has developed an innovative CAR-T technology, called MAR-T, for adoptive T cell cancer therapy.
Timmune's MAR-T utilizes a part of the proprietary TriTE construct as a multi-functional binding domain. As shown, the MAR binding domain (R1) binds to MHC antigen complex, IL15 and PD1 (R4&R5) improve the in-tumor micro-environment for solid tumor immunotherapies.
MAR-T/gp100 and/or MAR-T/wt1 are planned to go on clinical studies in 2017.
|Advantage over CAR-T||MAR-T binds to both MHC antigen complexes and cell surface targets - more targets for solid tumor immunotherapy.|
|Advantage over TCR-T||MAR-T has better MHC antigen complex binding specificity and affinity.|
|Other advantages||The extra-cellular domain contains IL15 and PD1, to stimulate T cells and block the check point. This will improve the in-tumor micro-environment for immunotherapy.|